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SHORT COMMUNICATION
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ABSTRACT
Recent years have seen increasing worldwide interest in the use of viscoelastic coagulation monitoring
tests, performed using devices such as ROTEM and TEG. The use of such tests to guide haemostatic
therapy may help reduce transfusion of allogeneic blood products in bleeding patients and is supported
in European guidelines for managing trauma and severe perioperative bleeding. In addition, viscoelastic
tests form the basis of numerous published treatment algorithms. However, some publications have
stated that viscoelastic tests are not validated. A specific definition of the term validation is lacking and
regulatory requirements of the US Food and Drug Administration (FDA) and European Medicines
Agency (EMA) have been fulfilled by ROTEM and TEG assays. Viscoelastic tests have been used in piv-
otal clinical trials, and they are approved for use in most of the world’s countries. Provided that locally
approved indications are adhered to, the regulatory framework for clinicians to use viscoelastic tests in
routine clinical practice is in place.
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Introduction
Perioperative monitoring of blood coagulation is important
for diagnosing the potential causes of bleeding and guiding
haemostatic therapy [1]. As a result, recent years have seen
increasing worldwide interest in the use of viscoelastic coagu-
lation monitoring tests, performed using devices such as
ROTEMVR (Tem International, Munich, Germany) and TEGVR
(Haemonetics, Braintree, MA, USA) [2–7]. The annual num-
ber of published clinical trials involving ROTEM or TEG
increased from eight in 2004 to 65 in 2014. Increased future
use of viscoelastic tests is anticipated as new devices with
increased automation (e.g. ROTEM sigma, TEG 6S) become
available. These devices are easier to use and have the poten-
tial to increase reproducibility compared with the previous
generation of devices, for reasons such as lack of need for
accurate pipetting, decreased sensitivity to external vibrations,
and electronic quality control before each measurement. The
main drawbacks with ROTEM sigma and TEG 6S are the
lack of peer-reviewed publications characterizing their per-
formance, and the fact that few clinicians have access to
these devices.
It is common for algorithms to be constructed as a means
of guiding haemostatic therapy in bleeding patients, and the
use of viscoelastic tests in preference to standard laboratory
tests as a basis for treatment decisions has been advocated
[8]. Such algorithms facilitate individualized goal-directed
therapy, with intended improvements such as reduced
transfusion of allogeneic blood products, reduced adverse
outcomes, reduced mortality and increased cost-effectiveness.
Evidence to support this approach exists in cardiac surgery
[9,10], trauma [11–13], postpartum haemorrhage [14] and
liver transplantation [15–17]. Notably, algorithms developed
for TEG or ROTEM are not interchangeable between the
two devices. This is because different assays are used with
each device, with differences between reagents and their con-
centrations even for equivalent assays. In addition, it has
been shown that when the same reagents are used, clot amp-
litude results are not consistent across the two devices [18].
Normal ranges and threshold values for intervention are spe-
cific to either TEG or ROTEM, necessitating specific algo-
rithms for each device. TEG and ROTEM results are based
on arbitrary, preset scales, meaning that they do not measure
absolute physical properties of the blood clot such as shear
modulus (G) [19].
The use of viscoelastic tests to characterize coagulopathy
and guide haemostatic therapy is endorsed in guidelines for
managing trauma, postpartum haemorrhage and severe peri-
operative bleeding [20–23]. A comprehensive UK NHS
assessment of viscoelastic tests concluded that they are more
effective than standard laboratory tests and cost saving [24].
In 2014, the UK National Institute for Health and Care
Excellence (NICE) recommended use of ROTEM and TEG
to monitor blood clotting during and after cardiac surgery
[25]. In trauma and post-partum haemorrhage, it was recom-
mended that ROTEM and TEG should only be used for
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research because of uncertainty as to how much benefit they
provide in these settings [25]. However, more recent data
have demonstrated the effectiveness of viscoelastic testing in
trauma and post-partum haemorrhage [14,24,26].
Existing evidence, not only relating to treatment algo-
rithms, shows potential for the use of ROTEM and TEG to
reduce transfusion of allogeneic blood products in bleeding
patients [9,24,27]. Viscoelastic coagulation tests have also
been shown to be cost-saving in both cardiac surgery and
trauma [24]. On the other hand, there is an absence of evi-
dence that TEG or ROTEM improves morbidity or mortality
in patients with severe bleeding [24,28]. This may be because
the devices and assays themselves do not change patient
care. Instead, improvements in morbidity and mortality are
dependent on clinicians’ interpretation of viscoelastic test
results and consequent treatment decisions. The availability
of therapeutic agents will also affect outcomes. The design of
treatment algorithms based on viscoelastic tests has much
greater potential impact on clinical outcomes than the initial
decision of whether to use viscoelastic tests.
There is some debate regarding the status of viscoelastic
tests and some publications have stated that they are not
validated [29–33]. In the most recent of these examples, the
authors wrote: ‘However TEG continues to be a second-
level hemostasis test due to the lack of its quality assurance
procedures and that TEG is not validated, as far as inter-
national standards are concerned’ [32]. This text is unclear
because no definition of the term ‘international standards’
is provided. However, such statements may lead to the reli-
ability of viscoelastic tests being questioned and cause con-
cern among clinicians applying these tests in clinical
practice.
Regulatory requirements for viscoelastic coagulation
monitoring tests
For market authorisation of in vitro diagnostic products such
as ROTEM and TEG, the FDA require data showing the
analytical performance characteristics including bias or
inaccuracy, imprecision and the analytical specificity and
sensitivity [34]. FDA regulatory requirements for in vitro
diagnostic products make no mention of the term
‘validation’.
In vitro diagnostic medical devices (e.g. ROTEM, TEG)
are not subject to pre-market authorization by a regulatory
authority in Europe, but to a conformity assessment which,
for the majority of devices, is carried out under the sole
responsibility of the manufacturer [35]. Once certified, devi-
ces bear the CE marking which allows them to circulate
freely in the EU/EFTA countries and Turkey. The regulations
specify that the performance characteristics of in vitro diag-
nostic medical devices support the intended purpose, and
that manufacturer-stated performance is achieved in relation
to analytical performance (e.g. accuracy [trueness and preci-
sion], bias, sensitivity, specificity, reproducibility) and clinical
performance (e.g. diagnostic sensitivity, diagnostic specificity,
positive and negative predictive value). No specific
requirements for validation are mentioned in the EU regula-
tions for in vitro diagnostic medical devices [35].
Calibration is necessary to ensure the accuracy of devices
providing quantitative information (e.g. measuring the con-
centration of a specific protein in plasma). It is also a consid-
eration with the ROTEM and TEG devices but, because
viscoelastic methods are semi-quantitative, formal calibration
such as proficiency testing or inter-laboratory comparison is
not a prerequisite. TEG 5000 devices are calibrated twice a
year using biological controls [36], and this could be consid-
ered as an alternative assessment protocol in line with practi-
ces recommended by the Clinical and Laboratory Standards
Institute [37]. ROTEM devices are calibrated during manu-
facture, and subsequent calibration procedures are not con-
sidered by the manufacturer to be required.
What is meant by ‘validation’?
‘Assay validation’ implies documented control of the test per-
formance according to predefined criteria, relating for
example to precision, linearity, accuracy, robustness, meas-
urement limits. Such validation per se does not improve the
assay quality, it simply attests the ‘quality check status’ (i.e.
the assay has been quality checked). ‘Clinical validation’ of
an assay is different, because it requires the assessment of
relevance to clinical practice. Key considerations include
comparability of the results with previous results, and evalu-
ation of the effects of factors that may be encountered in
clinical practice (e.g. variations in patient characteristics).
According to the US Food and Drug Administration
(FDA), ‘Analytical method validation is the process of dem-
onstrating that an analytical procedure is suitable for its
intended purpose’ [38]. The FDA also states that ‘Validation
data must be generated under a protocol approved by the
sponsor following current good manufacturing practices with
the description of methodology of each validation character-
istic and predetermined and justified acceptance criteria,
using qualified instrumentation’ [38]. The European
Medicines Agency (EMA) has defined validation with similar
wording to the FDA: ‘The objective of validation of an ana-
lytical procedure is to demonstrate that it is suitable for its
intended purpose’ [39].
Although not included within the definition of valid-
ation, methods for viscoelastic coagulation monitoring
must be shown to meet applicable international standards
to be considered as validated. For example, ISO 13485 sets
out the requirements for quality management systems
relating to medical devices, and IEC 62304 specifies the
software requirements. With comprehensive assessment of
accuracy, precision, interference, reagent stability, and ref-
erence ranges as well as software validation, both ROTEM
and TEG devices have been shown to meet all such applic-
able standards. The intention of quality control procedures
is to ensure consistent, accurate device performance. The
need for standardization of viscoelastic coagulation tests,
with regular external quality assessment to ensure accurate
results, has been highlighted in the literature [40–42].
Coefficients of variation require measurement using both
intra and inter-laboratory samples. However,
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standardization is complicated by the fact that plasma
would typically be used for this purpose, while in clinical
practice the viscoelastic coagulation tests are performed
using whole blood.
Have the viscoelastic tests been validated?
The ROTEM and TEG systems and their assays have been
CE marked, ISO certified and FDA approved. Market
authorization has therefore been granted in most of the
world’s countries. To achieve this recognition, performance
has been evaluated in accordance with the requirements
outlined above. Both devices are routinely used in many
centres to guide administration of haemostatic therapy, and
both devices have been used in pivotal licensing trials
[43–45]. Therefore, it is reasonable to state that the FDA and
EMA definitions of validation (‘suitable for intended pur-
pose’) have been met for both ROTEM and TEG. For the
regulatory approval, performance characteristics of the devi-
ces were demonstrated, meaning that ‘assay validation’ has
been achieved. Further evidence of assay validation for both
ROTEM and TEG is available from a significant number of
published studies, but it is beyond the scope of this publica-
tion to review these in detail.
Considering ‘clinical validation’, the reference method for
both ROTEM and TEG is thrombelastography as introduced
by Hartert in 1948 [46,47]. The TEG 5000 device uses meth-
odology that is closely based on the apparatus developed by
Hartert, and ROTEM assays have been shown to correlate
with this method [48–51]. Correlations between viscoelastic
test results and standard laboratory measurements have been
reported, e.g. between FIBTEM MCF and plasma fibrinogen
level [52] and between TEG maximum amplitude and plate-
let count [53]. However, ROTEM and TEG tests are con-
ducted differently from all standard laboratory coagulation
tests, meaning that differences are to be expected. For
example, the FIBTEM assay and plasma fibrinogen concen-
tration tests measure different physical properties with differ-
ent SI units, and fibrinogen is not the only determinant of
FIBTEM MCF [54,55]. Therefore, neither the FDA nor the
EMA has decreed that any of the standard laboratory coagu-
lation tests should be used as a reference method for
ROTEM or TEG tests. Cut-off values for the management of
coagulation in settings such as cardiovascular surgery, trauma
and obstetric/post-partum haemorrhage have been estab-
lished in numerous studies conducted with both ROTEM
and TEG. Detailed consideration of these data is beyond the
scope of this publication.
Conclusion
The use of ROTEM and TEG tests to diagnose coagulopathy
and determine haemostatic treatment – commonly when
implementing treatment algorithms – is increasing. Such use
of these tests is accepted by European and American regula-
tory bodies, both in clinical trials and routine practice.
Although the term ‘validation’ does not have a specific defin-
ition in relation to viscoelastic coagulation tests, relevant
criteria within EMA and FDA documentation are fulfilled.
There is evidence that viscoelastic coagulation tests can help
reduce transfusion rates and that they are cost-effective. In
addition, bleeding management guidelines support the use of
viscoelastic tests. ROTEM and TEG devices/assays have been
used in pivotal clinical trials and are approved for use in
most of the world’s countries. Provided that locally approved
indications are adhered to, the regulatory framework for
clinicians to use viscoelastic tests in routine clinical practice
is in place.
Acknowledgements
Editorial assistance was provided by Meridian HealthComms Ltd,
funded by CSL Behring.
Disclosure statement
Cristina Solomon is an employee of CSL Behring and previously
received speaker honoraria and research support from Tem
International and CSL Behring, and travel support from Haemoscope
Ltd (former manufacturer of TEG). Lars Asmis has received speaker
honoraria or research support from Axon Lab, Bayer, Boehringer
Ingelheim, CSL Behring, GlaxoSmithKline, Pfizer, Sanofi Aventis and
Vifor. Donat R. Spahn has received honoraria or travel support for con-
sulting or lecturing from the following companies: Abbott AG, Baar,
Switzerland; AMGEN GmbH, Munich, Germany; AstraZeneca AG, Zug,
Switzerland; Bayer (Schweiz) AG, Z€urich, Switzerland; Baxter AG,
Volketswil, Switzerland; Baxter S.p.A., Roma, Italy; B. Braun Melsungen
AG, Melsungen, Germany; Boehringer Ingelheim (Schweiz) GmbH,
Basel, Switzerland; Bristol-Myers-Squibb, Rueil-Malmaison Cedex,
France, and Baar, Switzerland; CSL Behring GmbH, Hattersheim am
Main, Germany, and Berne, Switzerland; Curacyte AG, Munich,
Germany; Ethicon Biosurgery, Sommerville, NJ, USA; Fresenius SE, Bad
Homburg v.d.H., Germany; Galenica AG, Bern, Switzerland (including
Vifor SA, Villars-sur-Gla^ne, Switzerland); GlaxoSmithKline GmbH &
Co. KG, Hamburg, Germany; Janssen-Cilag AG, Baar, Switzerland;
Janssen-Cilag EMEA, Beerse, Belgium; Merck Sharp & Dohme AG,
Luzern, Switzerland; Novo Nordisk A/S, Bagsv€ard, Denmark;
Octapharma AG, Lachen, Switzerland; Organon AG, Pf€affikon/SZ,
Switzerland; Oxygen Biotherapeutics, Costa Mesa, CA, USA; Photonics
Healthcare GmbH, Munich, Germany; ratiopharm Arzneimittel
Vertriebs-GmbH, Vienna, Austria; Roche Diagnostics International Ltd,
Reinach, Switzerland; Roche Pharma (Schweiz) AG, Reinach,
Switzerland; Schering-Plough International, Inc., Kenilworth, NJ, USA;
Tem International GmbH, Munich, Germany; Verum Diagnostica
GmbH, Munich, Germany; Vifor Pharma Deutschland GmbH, Munich,
Germany; Vifor Pharma €Osterreich GmbH, Vienna, Austria; and Vifor
(International) AG, St. Gallen, Switzerland.
References
1. Kozek-Langenecker SA. Perioperative coagulation monitoring.
Best Pract Res Clin Anaesthesiol 2010;24:27–40.
2. Coelho MC, Vieira Neto L, Kasuki L, Wildemberg LE, Santos
CV, Castro G, Gouvea G, Veloso OC, Gadelha T, Gadelha MR.
Rotation thromboelastometry and the hypercoagulable state in
Cushing’s syndrome. Clin Endocrinol (Oxf) 2014;81:657–64.
3. Ghavidel AA, Toutounchi Z, Shahandashti FJ, Mirmesdagh Y.
Rotational thromboelastometry in prediction of bleeding after car-
diac surgery. Asian Cardiovasc Thorac Ann 2015;23:525–9.
4. Sawhney C, Subramanian A, Kaur M, Anjum A, Albert V, Soni
KD, Kumar A. Assessment of hemostatic changes after crystalloid
and colloid fluid preloading in trauma patients using standard
coagulation parameters and thromboelastography. Saudi J
Anaesth 2013;7:48–56.
SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION 505
5. Chen GY, Ou Yang XL, Wu JH, Wang LH, Yang JH, Gu LN, Lu
ZJ, Zhao XZ. [Comparison of thromboelastography and routine
coagulation tests for evaluation of blood coagulation function in
patients]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2015;23:546–51.
6. Da Luz LT, Nascimento B, Shankarakutty AK, Rizoli S, Adhikari
NK. Effect of thromboelastography (TEGV
R
) and rotational throm-
boelastometry (ROTEMV
R
) on diagnosis of coagulopathy, transfu-
sion guidance and mortality in trauma: descriptive systematic
review. Crit Care 2014;18:518.
7. McDaniel LM, Etchill EW, Raval JS, Neal MD. State of the art:
massive transfusion. Transfus Med 2014;24:138–44.
8. Weber CF, Zacharowski K, Meybohm P, Adam EH, Hofer S,
Brun K, Volk T, Kreuer S. Hemotherapy algorithms for coagulo-
pathic cardiac surgery patients. Clin Lab 2014;60:1059–63.
9. Gorlinger K, Dirkmann D, Hanke AA, Kamler M, Kottenberg E,
Thielmann M, Jakob H, Peters J. First-line therapy with coagula-
tion factor concentrates combined with point-of-care coagulation
testing is associated with decreased allogeneic blood transfusion
in cardiovascular surgery: a retrospective, single-center cohort
study. Anesthesiology 2011;115:1179–91.
10. Weber CF, Gorlinger K, Meininger D, Herrmann E, Bingold T,
Moritz A, Cohn LH, Zacharowski K. Point-of-care testing: a pro-
spective, randomized clinical trial of efficacy in coagulopathic car-
diac surgery patients. Anesthesiology 2012;117:531–47.
11. Nardi G, Agostini V, Rondinelli B, Russo E, Bastianini B, Bini G,
Bulgarelli S, Cingolani E, Donato A, Gambale G, Ranaldi G.
Trauma-induced coagulopathy: impact of the early coagulation
support protocol on blood product consumption, mortality and
costs. Crit Care 2015;19:83.
12. Schochl H, Nienaber U, Maegele M, Hochleitner G, Primavesi F,
Steitz B, Arndt C, Hanke A, Voelckel W, Solomon C.
Transfusion in trauma: thromboelastometry-guided coagulation
factor concentrate-based therapy versus standard fresh frozen
plasma-based therapy. Crit Care 2011;15:R83.
13. Spahn DR. TEGV
R
- or ROTEMV
R
-based individualized goal-
directed coagulation algorithms: don’t wait – act now! Crit Care
2014;18:637.
14. Mallaiah S, Barclay P, Harrod I, Chevannes C, Bhalla A.
Introduction of an algorithm for ROTEM-guided fibrinogen con-
centrate administration in major obstetric haemorrhage.
Anaesthesia 2015;70:166–75.
15. Leon-Justel A, Noval-Padillo JA, Alvarez-Rios AI, Mellado P,
Gomez-Bravo MA, Alamo JM, Porras M, Barrero L, Hinojosa R,
Carmona M, Vilches-Arenas A, Guerrero JM. Point-of-care
haemostasis monitoring during liver transplantation reduces
transfusion requirements and improves patient outcome. Clin
Chim Acta 2015;446:277–83.
16. Roullet S, Freyburger G, Cruc M, Quinart A, Stecken L, Audy M,
Chiche L, Sztark F. Management of bleeding and transfusion dur-
ing liver transplantation before and after the introduction of a
rotational thromboelastometry-based algorithm. Liver Transpl
2015;21:169–79.
17. Kirchner C, Dirkmann D, Treckmann JW, Paul A, Hartmann M,
Saner FH, Gorlinger K. Coagulation management with factor con-
centrates in liver transplantation: a single-center experience.
Transfusion 2014;54:2760–8.
18. Solomon C, Sorensen B, Hochleitner G, Kashuk J, Ranucci M,
Schochl H. Comparison of whole blood fibrin-based clot tests in
thrombelastography and thromboelastometry. Anesth Analg
2012;114:721–30.
19. Hochleitner G, Sutor K, Levett C, Leyser H, Schlimp CJ, Solomon
C. Revisiting Hartert’s 1962 calculation of the physical constants
of thrombelastography. Clin Appl Thromb Hemost 2015. [Epub
ahead of print]. doi: 10.1177/1076029615606531.
20. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA,
De Robertis E, Filipescu DC, Fries D, Gorlinger K, Haas T,
Imberger G, Jacob M, Lance M, Llau J, Mallett S, Meier J, Rahe-
Meyer N, Samama CM, Smith A, Solomon C, Van der Linden P,
Wikkelso AJ, Wouters P, Wyffels P. Management of severe
perioperative bleeding: guidelines from the European Society of
Anaesthesiology. Eur J Anaesthesiol 2013;30:270–382.
21. Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J,
Fernandez-Mondejar E, Filipescu D, Hunt BJ, Komadina R, Nardi
G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent JL,
Rossaint R. Management of bleeding and coagulopathy following
major trauma: an updated European guideline. Crit Care
2013;17:R76.
22. American Society of Anesthesiologists Task Force on
Perioperative Blood Management. Practice guidelines for peri-
operative blood management: an updated report by the American
Society of Anesthesiologists task force on perioperative blood
management. Anesthesiology 2015;122:241–75.
23. Collins P, Abdul-Kadir R, Thachil J, The Subcommittees on
Women’s Health Issues in Thrombosis and Haemostasis and on
Disseminated Intravascular Coagulation. Management of coagul-
opathy associated with postpartum hemorrhage: guidance from
the SSC of the ISTH. J Thromb Haemost 2016;14:205–10.
24. Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong
N, Misso K, Ross J, Severens J, Kleijnen J. Viscoelastic point-of-
care testing to assist with the diagnosis, management and moni-
toring of haemostasis: a systematic review and cost-effectiveness
analysis. Health Technol Assess 2015;19:1–228.
25. National Institute for Health and Care Excellence. Detecting,
managing and monitoring haemostasis: viscoelastometric point-
of-care testing (ROTEM, TEG and Sonoclot systems). NICE diag-
nostics guidance [DG13]. 2014. Available from: https://www.nice.
org.uk/guidance/dg13 [last accessed February 2016].
26. Gonzalez E, Moore EE, Moore HB, Chapman MP, Chin TL,
Ghasabyan A, Wohlauer MV, Barnett CC, Bensard DD, Biffl WL,
Burlew CC, Johnson JL, Pieracci FM, Jurkovich GJ, Banerjee A,
Silliman CC, Sauaia A. Goal-directed hemostatic resuscitation of
trauma-induced coagulopathy: a pragmatic randomized clinical
trial comparing a viscoelastic assay to conventional coagulation
assays. Ann Surg 2015;263:1051–9.
27. Schaden E, Kimberger O, Kraincuk P, Baron DM, Metnitz PG,
Kozek-Langenecker S. Perioperative treatment algorithm for
bleeding burn patients reduces allogeneic blood product require-
ments. Br J Anaesth 2012;109:376–81.
28. Afshari A, Wikkelso A, Brok J, Moller AM, Wetterslev J.
Thrombelastography (TEG) or thromboelastometry (ROTEM) to
monitor haemotherapy versus usual care in patients with massive
transfusion. Cochrane Database Syst Rev 2011;16:CD007871.
29. Samama CM, Ozier Y. Near-patient testing of haemostasis in the
operating theatre: an approach to appropriate use of blood in sur-
gery. Vox Sang 2003;84:251–5.
30. Gaunt C, Woolley T. Management of haemorrhage in major
trauma. Contin Educ Anaesth Crit Care Pain 2014;14:251–5.
31. Sie P, Steib A. Central laboratory and point of care assessment of
perioperative hemostasis. Can J Anaesth 2006;53:S12–20.
32. Subramanian A, Albert V, Agrawal D, Saxena R, Pandey RM.
Evaluation of the utility of thromboelastography in a tertiary
trauma care centre. ISRN Hematol 2014;2014:849626.
33. Samama CM. Thromboelastography: the next step. Anesth Analg
2001;92:563–4.
34. US Food and Drug Administration. Overview of IVD Regulation.
2015. Available from: http://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/IVDRegulatoryAssistance/
ucm123682.htm#1 [last accessed November 2015].
35. European Commission. Proposal for a regulation of the European
Parliament and of the council on in vitro diagnostic medical devi-
ces. 2012. Available from: http://ec.europa.eu/health/medical-devi-
ces/files/revision_docs/proposal_2012_541_en.pdf [last accessed
October 2015].
36. Haemoscope Corporation. TEG 5000 Thrombelastograph hemo-
stasis system: user manual. 2015. Available from: http://diamedil.
info/MediGal/Technical%20Support/PN06-510_TEG_UserManual
_v4_3_2008-10.PDF [last accessed November 2015].
37. Clinical and Laboratory Standards Institute. Assessment of
laboratory tests when proficiency testing is not available;
506 C. SOLOMON ET AL.
Approved guideline: second edition. 2008. Available from: http://
shop.clsi.org/GP29.html [last accessed November 2015].
38. US Department of Health and Human Services (Food and Drug
Administration). Analytical procedures and methods validation
for drugs and biologics – guidance for industry. 2015. Available
from: www.fda.gov/downloads/drugs/guidancecomplianceregula-
toryinformation/guidances/ucm386366.pdf [last accessed October
2015].
39. European Medicines Agency. Validation of analytical procedures:
text and methodology. 1995. Available from: http://www.ema.eur-
opa.eu/docs/en_GB/document_library/Scientific_guideline/2009/
09/WC500002662.pdf [last accessed October 2015].
40. Chitlur M, Lusher J. Standardization of thromboelastography: val-
ues and challenges. Semin Thromb Hemost 2010;36:707–11.
41. Kitchen DP, Kitchen S, Jennings I, Woods T, Walker I. Quality
assurance and quality control of thrombelastography and rota-
tional thromboelastometry: the UK NEQAS for blood coagulation
experience. Semin Thromb Hemost 2010;36:757–63.
42. Marlar RA, Gausman JN, Engel JW. Validation of hemostasis and
coagulation assays: recommendations and guidelines. Semin
Thromb Hemost 2014;40:186–94.
43. ClinicalTrials.gov. Study of fibrinogen concentrate (Human)
(FCH) to control bleeding during complex cardiovascular surgery
(REPLACE). 2015. Available from: https://clinicaltrials.gov/ct2/
show/NCT01475669 [last accessed November 2015].
44. Manco-Johnson MJ, Dimichele D, Castaman G, Fremann S,
Knaub S, Kalina U, Peyvandi F, Piseddu G, Mannucci P,
Fibrinogen Concentrate Study Group. Pharmacokinetics and
safety of fibrinogen concentrate. J Thromb Haemost
2009;7:2064–9.
45. Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D,
Hochleitner G, Sorensen B, Hagl C, Pichlmaier M. Effects of
fibrinogen concentrate as first-line therapy during major aortic
replacement surgery: a randomized, placebo-controlled trial.
Anesthesiology 2013;118:40–50.
46. Hartert H. [Blutgerinnungsstudien mit der Thrombelastographie;
einem neuen Untersuchungs verfahren]. Klin Wochenschr
1948;26:577–83.
47. Sch€ochl H, Solomon C, Voelckel W. Thromboelastometry in the
perioperative setting. Neth J Crit Care 2010;14:23–31.
48. Calatzis A, Calatzis A, Fritzsche P, Kling M, Hipp R, Stemberger
A. An analysis of the correlation of the ROTEG coagulation ana-
lyzer and the Hellige Thrombelastograph. D Ann Hematol
1996;72:P87.
49. Calatzis A, Kling M, Stemberger A, Calatzis A, Hipp R, Bluemel
G. Pitfalls in the application of TEG during liver transplantation
and ways to escape. Ann Hematol 1995;70:A21.
50. Fritzsche P, Calatzis A, Stemberger A, Calatzis A. The ROTEG-4
coagulation analyzer: technology and precision. Ann Hematol
1998;76:A88.
51. Lang T, Bauters A, Braun SL, Potzsch B, von Pape KW, Kolde
HJ, Lakner M. Multi-centre investigation on reference ranges for
ROTEM thromboelastometry. Blood Coagul Fibrinolysis
2005;16:301–10.
52. Haas T, Spielmann N, Mauch J, Madjdpour C, Speer O,
Schmugge M, Weiss M. Comparison of thromboelastometry
(ROTEMV
R
) with standard plasmatic coagulation testing in paedi-
atric surgery. Br J Anaesth 2012;108:36–41.
53. Alexander DC, Butt WW, Best JD, Donath SM, Monagle PT,
Shekerdemian LS. Correlation of thromboelastography with
standard tests of anticoagulation in paediatric patients receiving
extracorporeal life support. Thromb Res 2010;125:387–92.
54. Solomon C, Cadamuro J, Ziegler B, Schochl H, Varvenne M,
Sorensen B, Hochleitner G, Rahe-Meyer N. A comparison of
fibrinogen measurement methods with fibrin clot elasticity
assessed by thromboelastometry, before and after administration
of fibrinogen concentrate in cardiac surgery patients. Transfusion
2011;51:1695–706.
55. Solomon C, Rahe-Meyer N, Schochl H, Ranucci M, Gorlinger K.
Effect of haematocrit on fibrin-based clot firmness in the
FIBTEM test. Blood Transfus 2013;11:412–18.
SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION 507
